Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD

Written by Customer Service on June 10, 2023. Posted in Public Companies.

OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in treatment burden over a 12-month period OTX-TKI demonstrated no drug-related ocular or systemic serious adverse events in the trial through Month 12 Implant observed to bioresorb consistently at about eight to nine months in trial, informing potential redosing timeline Investor/analyst conference call to discuss results to be held on Monday, June 12, at 8:30 a.m. ET BEDFORD, Mass., June 10, 2023 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of the eye, today announced 12-month data from its Phase 1 U.S. clinical trial evaluating OTX-TKI, the Company’s axitinib intravitreal hydrogel...

Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

Written by Customer Service on June 10, 2023. Posted in Public Companies.

Posters highlight clinically meaningful improvement in HAE symptoms observed in the first hours after treatment with PHVS416 (deucrictibant immediate-release capsules) as compared to placebo ZUG, Switzerland, June 11, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced two presentations highlighting data from RAPIDe-1, a Phase 2 study of PHVS416 (deucrictibant immediate-release capsules) for the on-demand treatment of HAE attacks, included in the “Flash Talks on Angioedema” session at the European Academy of Allergy & Clinical Immunology (EAACI) Hybrid Congress 2023, taking place in Hamburg, Germany, from June 9-11, 2023. Presentation details: Title: Treatment with Oral...

Aptose Presents Highlights from Clinical Update

Written by Customer Service on June 10, 2023. Posted in Public Companies.

Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat R/R AML PopulationsTP53MUT CR/CRh = 20% │ RASMUT CR/CRh = 22% Completed Successful Type B EOP1 Meeting with US FDAMonotherapy RP2D selected as 80mg daily and single arm accelerated path remains open Initiated APTIVATE Expansion Trial with R/R AMLTuspetinib monotherapy and Tuspetinib + Venetoclax (TUS/VEN) doublet show brisk enrollmentTUS/VEN doublet well tolerated, all patients remain on study, preliminary CR activity reported among first patients treated SAN DIEGO and TORONTO, June 10, 2023 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...

Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate

Written by Customer Service on June 10, 2023. Posted in Public Companies.

Data on CD19/BCMA dual-targeting FasTCAR-T GC012F showed 100% overall response rate (ORR) and 66.7% 6-month complete response (CR) rate among treated patients, all with diffuse large B-cell lymphoma (DLBCL) subtype Data on GC012F for treatment of relapsed/refractory multiple myeloma (RRMM) and donor-derived CAR-T GC007g for treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) have been presented as posters on June 9 at EHA2023 SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, June 10, 2023 (GLOBE NEWSWIRE) — Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today presented longer-term...

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Written by Customer Service on June 10, 2023. Posted in Public Companies.

7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose in the Phase 1 dose escalation study Data demonstrate potential for redosing of allogeneic CD19 CAR NK to deepen response or restore response post-relapse Majority of patients achieved CR after a single cycle of NKX019 Early safety data support potential of allogeneic CD19 CAR NK to be administered on outpatient basis No neurotoxicity / ICANS, graft versus host disease (GvHD), or > Gr3 cytokine release syndrome (CRS) 40% of eligible patients received NKX019 in the outpatient setting after first cycle SOUTH SAN FRANCISCO, Calif., June 10, 2023 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell...

Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023

Written by Customer Service on June 10, 2023. Posted in Public Companies.

– Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment landscape –– At week 24, 55% of all patients with CSU in the 1.5 mg/kg, 3.0 mg/kg and 4.5 mg/kg dose groups had complete response (UAS7) and 69% had well-controlled disease (UCT) –– Patients in the CSU study with angioedema treated at these doses had profound and durable angioedema symptom improvement –– Single 3.0 mg/kg dose of barzolvolimab was well tolerated and demonstrated impressive clinical activity in difficult to treat cholinergic urticaria with a 56% complete response rate and patients reporting clinically significant improvement in quality of life –– Phase 2 CSU study nearing enrollment completion with topline data by year-end; Phase 2...

Barrick Paves the Way for Reintroduction of White Rhino to Garamba National Park

Written by Customer Service on June 10, 2023. Posted in Public Companies.

All amounts expressed in US dollars GARAMBA NATIONAL PARK, Democratic Republic of Congo, June 10, 2023 (GLOBE NEWSWIRE) — An initiative begun by Barrick president and chief executive Mark Bristow almost 13 years ago has come to fruition with the successful reintroduction of 16 white rhinos to the Garamba National Park in the northeast of the DRC, where the species was last seen in 2006. Following more than a decade of dedicated action and support, an environment has been created where they can exist safely. The rhino arrived by aircraft from South Africa this week and have now been released in the park where professional staff and qualified veterinarians will regularly monitor their acclimatization. Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) was the lead donor in the translocation as part of its long-standing partnership with...

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Written by Customer Service on June 10, 2023. Posted in Public Companies.

NEW YORK and VIENNA, Austria, June 10, 2023 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to new employees to purchase an aggregate of 80,000 shares of the Company’s Common Stock under HOOKIPA’s 2023 Inducement Plan. The award was granted as an inducement material to the employees’s acceptance of employment with HOOKIPA in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $ 1.01 per share. The options have a ten year term and vest over four years, with 25% vesting on the one-year anniversary of the grant date and the remainder vesting in equal...

Three Sixty Solar Announces Closing of Initial Tranche of Non-Brokered Private Placements

Written by Customer Service on June 10, 2023. Posted in Public Companies.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 09, 2023 (GLOBE NEWSWIRE) — Three Sixty Solar Ltd. (the “Company”) (VSOL: NEO) is pleased to announce it has closed an initial tranche of its previously announced non-brokered private placement, issuing 1,669,900 units of the Company (“Units“) at a price of $0.60 per Unit for aggregate gross proceeds of $1,001,940.00 (the “LIFE Offering“). The Company has also closed an initial tranche of a concurrent non-brokered private placement, previously announced in its news released dated May 19, 2023 (the “Concurrent Offering”, and together with the LIFE Offering, the “Offering”), issuing 45,653 Units at a price of $0.60 per Unit for aggregate gross proceeds of $27,391.80. Each Unit is comprised...

onsemi to Join the Nasdaq-100 Index Beginning June 20, 2023

Written by Customer Service on June 10, 2023. Posted in Public Companies.

NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced that onsemi (Nasdaq: ON) will become a component of the Nasdaq -100 Index® (Nasdaq: NDX), the Nasdaq -100 Equal Weighted Index (Nasdaq: NDXE), the Nasdaq -100 Tech Sector Index (Nasdaq: NDXT), and the Nasdaq -100 ESG Index (Nasdaq: NDXESG) prior to market open on Tuesday, June 20, 2023. onsemi will replace Rivian Automotive, Inc. (Nasdaq: RIVN) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted Index. Rivian Automotive, Inc. will also be removed from the Nasdaq -100 ESG Index (Nasdaq: NDXESG) and the Nasdaq -100 Ex-Tech Sector Index (Nasdaq: NDXX) prior to market open on Tuesday, June 20, 2023. onsemi will be removed from the Nasdaq Q-50 Index (Nasdaq: NXTQ), Nasdaq Next Generation 100 Index (Nasdaq: NGX), and Nasdaq Next Generation 100 ESG...

Day: June 10, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice